| Comparison of various hormonal therapies for prostatic carcinoma. | |
| | |
MedLine Citation:
|
PMID: 6199846 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The goals of hormonal therapy for prostatic cancer are to decrease circulating plasma testosterone to castration levels; prevent a rise in or reduce circulating prolactin; and block residual androgen at the cell level. Orchiectomy is very effective but does not prevent residual adrenal androgens from being converted to dihydrotestosterone (DHT); also, it has no effect on plasma prolactin. Estrogen has no known effect on androgen-receptor concentration or DHT binding to receptor and raises plasma prolactin. It also has significant side effects. Megestrol acetate, the only antiandrogen currently available for use in the United States, has been shown to block androgen from all sources. It produces a transient reduction in plasma testosterone to levels somewhat higher than those in castrated men, and it has no effect on plasma prolactin. When used in a dose of 120 mg/day in combination with 0.5 to 1.5 mg of estradiol per day, it acts synergistically to suppress pituitary gonadotropins and maintain plasma testosterone at castration levels for periods of up to 1 year. Newer therapies being studied include flutamide, a nonsteroidal antiandrogen, and luteinizing hormone-releasing hormone (LHRH). Data on these agents are limited and comparisons with standard therapies are needed. |
| | |
Authors:
|
J Geller; J D Albert |
Related Documents
:
|
3211806 - Prognostic value of serum hormone concentrations in prostatic cancer. 2220936 - Suppression of serum insulin level by diazoxide does not alter serum testosterone or se... 19372016 - Hormonal changes during menopause. 3940696 - Concentrations of sex-hormone binding globulin and corticosteroid binding globulin in s... 6160076 - Aging changes of pancreatic isoamylases and the appearance of "old amylase" in the seru... 6796316 - Selective deficiency of the fourth component of complement in a patient with systemic l... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Seminars in oncology Volume: 10 ISSN: 0093-7754 ISO Abbreviation: Semin. Oncol. Publication Date: 1983 Dec |
Date Detail:
|
Created Date: 1984-04-02 Completed Date: 1984-04-02 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0420432 Medline TA: Semin Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 34-41 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Androgen Antagonists
/
therapeutic use* Androgens / metabolism Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Binding, Competitive Castration Dihydrotestosterone / metabolism Estradiol / administration & dosage Humans Male Megestrol / administration & dosage, analogs & derivatives Megestrol Acetate Palliative Care Prolactin / metabolism Prostatic Neoplasms / drug therapy*, metabolism Receptors, Androgen / metabolism Testosterone / blood, metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
2 R 26-CA18003-07/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Androgen Antagonists; 0/Androgens; 0/Receptors, Androgen; 3562-63-8/Megestrol; 50-28-2/Estradiol; 51154-23-5/Megestrol Acetate; 521-18-6/Dihydrotestosterone; 58-22-0/Testosterone; 9002-62-4/Prolactin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor.
Next Document: Accuracy of staining technique for detecting mycobacterial infection.